Abemaciclib for advanced tumors with cyclin or CDK4/6 gene changes
Treatments studied
Part of Cancer clinical trials.
This Phase 2 study tests abemaciclib, a targeted cancer medicine, in people with advanced solid tumors that have specific gene changes related to cyclin D or CDK4/6. The goal is to see how well it controls tumors when standard treatments don’t work or aren’t available.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have an advanced solid tumor (not breast cancer) with a confirmed gene change in CCND1 (cyclin D1) and/or CDK4 or CDK6—based on tumor testing from an approved lab.
- Your cancer is measurable/evaluable, meaning doctors can track it on scans or tests.
- You’re age 18 or older, and your overall health is good enough for treatment (ECOG 0–1).
- Your blood counts and organ function (liver/kidney) are at acceptable levels based on lab tests.
- You can take pills by mouth, understand the study, and sign informed consent.
- You can use reliable birth control (or abstain) during the study and for 3 months after the last dose; pregnancy and breastfeeding are not allowed.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests whether adding medicines to standard hormone therapy (letrozole) can control endometrial cancer that has come back, spread, or stopped responding to usual treatments. It also explores whether extra drugs (metformin or gedatolisib) improve results for certain patient groups.
This trial tests abemaciclib (a cancer medicine) in adults with advanced, unresectable bone or soft-tissue sarcoma that has certain gene changes in the “CDK pathway.” It aims to shrink tumors or slow growth in people whose tumors match the study’s biomarker and lab requirements.
This Phase 2 study tests abemaciclib, a targeted pill treatment, for recurrent ovarian or endometrial cancer that shows specific tumor genetic patterns. It may help slow or control cancer growth in people whose tumor matches the required test results.
This trial tests a drug called abemaciclib for people with early-stage, hormone-receptor-positive, HER2-negative breast cancer who still have cancer DNA in their blood after completing standard treatment. It aims to see if taking this drug can reduce the chance of cancer coming back.
This Phase 2 study tests whether abemaciclib combined with standard hormone (endocrine) therapy can better control metastatic breast cancer in people age 70 and older. It may help if your cancer has already grown despite prior hormone therapy and/or other cancer medicines.
This trial tests whether a higher dose of abemaciclib (a pill that helps stop cancer cells from growing) is safe and effective when used after surgery for early high-risk breast cancer. It is for people whose cancer is hormone receptor positive and HER2 negative, and who will take it along with endocrine therapy (hormone-blocking treatment).
Hear when a new Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.